Recce Ltd has released a press release.
Positive Safety Continues in 3rd Cohort PhI Clinical Trial
Filed with ASX ·
6ix hasn’t read this filing yet.
Recce Pharmaceuticals Ltd. on 6ix
Story so far
Earlier from Recce Pharmaceuticals
- Positive Safety Data from Third Cohort of PI Clinical Trial
- Positive Safety Data from Second Cohort of PI Clinical Trial
- Positive Safety Data from Phase 1 Clinical Trial
- Patients to be Dosed in Ph 1 IV Clinical Trial of R327
- Update on Phase I/II Clinical Trial for Burn Wound Infection
Later from Recce Pharmaceuticals
- S&P DJI Announces March 2022 Quarterly Rebalance
- Safety Committee Clears PhI R327 Dose Increase
- $3.08m R&D Rebate Received
- Positive safety data from 4th Cohort -Phase I Clinical Trial
- Anti-Viral Patent Granted in Hong Kong
Follow Recce Pharmaceuticals into a list and get an email when it puts out news.
Follow Recce Pharmaceuticals